Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that a variety of barriers may hinder the sales of radioimmunotherapies in the aggressive non-Hodgkin's lymphoma drug market.

"Companies investigating radioimmunotherapies to treat aggressive non- Hodgkin's lymphoma -- such as Corixa/GlaxoSmithKline and Biogen Idec -- will continue to struggle to overcome multiple barriers to uptake, including coordination difficulties between oncologists and the nuclear medicine physicists who will administer these therapies; regulatory and reimbursement challenges; and, certainly most significant in the United States, referral disincentives for office-based oncologists," said Mary Fletcher-Louis, analyst at Decision Resources.

According to the new Pharmacor study entitled Non-Hodgkin's Lymphoma, results of a forthcoming head-to-head trial between two radioimmunotherapies, 90Y-ibritumomab and 131I-tositumomab, in the indolent non-Hodgkin's lymphoma setting and sponsored by Corixa/GlaxoSmithKline, will be the principal determinant of market share distribution between the two agents.

About Non-Hodgkin's Lymphoma

Non-Hodgkin's lymphomas constitute the fifth most common cancer in the United States. In terms of pharmaceutical sales, non-Hodgkin's lymphoma ranks fourth after breast cancer, non-small-cell lung cancer, and colorectal cancer. Approximately 40% of non-Hodgkin's lymphomas follow an indolent course; the remaining non-Hodgkin's lymphomas are aggressive tumors.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., (www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,
emarshall@dresources.com

Although More-Expensive Atypical Antipsychotics Will Drive the Schizophrenia Drug Market, they Will Face Tough Competition from Generics

View Now